Donor and Recipient Mismatch in Liver Transplantation (DR-MM in LT)

February 10, 2026 updated by: Nicola Sariye Pollmann, University of Jena

Donor and Recipient Mismatch in Liver Transplantation - Time for Reconsideration?

This observational study aims to investigate the impact of gender disparity between donors and recipients on long-term outcomes after liver transplantation (LT). The study aims to answer the following question:

Does gender mismatch lower the possibility of survival after liver transplantation? Participants demonstrate gender dicrepancies between donors and recipients as regular concept in LT. The retrospective cohort study investigates the impact over a long-term follow up of 10 years.

Study Overview

Status

Completed

Conditions

Detailed Description

The study involves patients who undergo liver transplantation at the Ajmera Transplant Centre Toronto from 2014 until 2022. The observation period ended at the first January 2025 to provide a minimal follow up of 24 months.

Liver transplant recipients with gender mismatch (A) will be compared with liver transplant recipients without gender mismatch (B).

Liver transplantation is the only curative treatment for people with end stage liver disease. Gender mismatch between donor and recipient, particularly, the combination of a female donor to male recipient has been controversial in the past. Identifying risk factors that could affect the survival of the graft and recipient is of the utmost importance.

Study Type

Observational

Enrollment (Actual)

1146

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada
        • Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients who underwent liver transplantation at who at the Ajmera transplant centre, Toronto between 2014 and 2022

Description

Inclusion Criteria:

  • Patients over the age of 18

Exclusion Criteria:

  • Cases of retransplantation
  • Combined organ transplantation
  • Cases with >30% of missing values

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
GM +
Liver transplant recipients with gender mismatch
GM -
Liver transplant recipients without gender mismatch

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient survival
Time Frame: Liver transplantation between 01.01.2014 and 01.01.2022, Patient Survival: observatory period between 01.01.2014 and 01.01.2024
Overall survival of patients who underwent liver transplantation at the Ajmera transplant centre toronto between 2014 and 2022
Liver transplantation between 01.01.2014 and 01.01.2022, Patient Survival: observatory period between 01.01.2014 and 01.01.2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Jena

Collaborators

University Health Network, Toronto

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2014

Primary Completion (Actual)

January 1, 2022

Study Completion (Actual)

January 1, 2024

Study Registration Dates

First Submitted

November 18, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Actual)

November 26, 2025

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 10, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20-5877.4

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The investigators consider not to share IPD before publishing the study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Transplant Surgery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe